These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 3993298)

  • 1. [Method of treating parkinsonism with metamizil in combination with galanthamine (clinico-experimental basis)].
    Losev NA; Kamenetskiĭ VK
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1985; 85(3):376-81. PubMed ID: 3993298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of N- and M-cholinergic-potentiating and cholinergic-blocking agents on the epileptogenesis of a penicillin focus in the dorsal hippocampus].
    Losev NA; Tkachenko EI
    Biull Eksp Biol Med; 1986 Apr; 101(4):436-8. PubMed ID: 2870750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Experience in treating vascular parkinsonism with metamysil].
    Kamenetskiĭ VK
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1978; 78(3):365-70. PubMed ID: 645311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Combined administration of cholinolytic metamizil and L-Dopa in vascular parkinsonism].
    Kamenetskiĭ VK
    Klin Med (Mosk); 1978 Sep; 56(9):113-5. PubMed ID: 703225
    [No Abstract]   [Full Text] [Related]  

  • 5. [Role of M- and N-cholinergic systems in the recovery of motor functions after removal of the motor zones of the cerebral cortex in cats].
    Shalkovskaia LN; Losev NA
    Zh Vyssh Nerv Deiat Im I P Pavlova; 1984; 34(6):1066-71. PubMed ID: 6524065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of subchronic galantamine treatment on neuronal nicotinic and muscarinic receptor subtypes in transgenic mice overexpressing human acetylcholinesterase.
    Svedberg MM; Bednar I; Nordberg A
    Neuropharmacology; 2004 Sep; 47(4):558-71. PubMed ID: 15380373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Correction of apathetic-abulic manifestations of schizophrenia with cholinotropic drugs].
    Vovin RIa; Fakturovich AIa; Golenkov AV; Lukin VO
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1991; 91(2):111-5. PubMed ID: 1647606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Combined use of metamizil and midantan in vascular parkinsonism].
    Kamenetskiĭ VK
    Klin Med (Mosk); 1979 Sep; 57(9):59-62. PubMed ID: 491516
    [No Abstract]   [Full Text] [Related]  

  • 9. [Participation of m- and n-cholinergic mechanisms in the development of the kindling phenomenon of the amygdala in cats].
    Losev NA; Shalkovskaia LN
    Biull Eksp Biol Med; 1985 May; 99(5):580-3. PubMed ID: 4005413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of M- and N-cholinergic biosystems of the brain in the mechanisms responsible for optokinetic, postoptokinetic, and reversed postoptokinetic nystagmus].
    Neverov VP; Losev NA
    Fiziol Zh SSSR Im I M Sechenova; 1981 May; 67(5):738-43. PubMed ID: 6116627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early idiopathic parkinsonism: initiation and optimization of treatment.
    Calne DB
    Clin Neuropharmacol; 1994; 17 Suppl 2():S14-8. PubMed ID: 9358191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.
    Prescrire Int; 2007 Oct; 16(91):197-8. PubMed ID: 17926835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Muscarinic and nicotinic presynaptic modulation of EPSCs in the nucleus accumbens during postnatal development.
    Zhang L; Warren RA
    J Neurophysiol; 2002 Dec; 88(6):3315-30. PubMed ID: 12466449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro galantamine-memantine co-application: mechanism of beneficial action.
    Zhao X; Marszalec W; Toth PT; Huang J; Yeh JZ; Narahashi T
    Neuropharmacology; 2006 Dec; 51(7-8):1181-91. PubMed ID: 17011596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Trans-cerebral electrophoresis of L-DOPA in the complex treatment of parkinsonism].
    Neĭmark EZ; Evtushenko SK; Dukhovnaia MA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1984; 84(9):1334-8. PubMed ID: 6506979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic effect of combined treatment with risperidone and galantamine on phencyclidine-induced impairment of latent visuospatial learning and memory: Role of nAChR activation-dependent increase of dopamine D1 receptor-mediated neurotransmission.
    Wang D; Noda Y; Zhou Y; Nitta A; Furukawa H; Nabeshima T
    Neuropharmacology; 2007 Sep; 53(3):379-89. PubMed ID: 17632185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease.
    Geerts H; Grossberg GT
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):8S-16S. PubMed ID: 16809810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors.
    Samochocki M; Höffle A; Fehrenbacher A; Jostock R; Ludwig J; Christner C; Radina M; Zerlin M; Ullmer C; Pereira EF; Lübbert H; Albuquerque EX; Maelicke A
    J Pharmacol Exp Ther; 2003 Jun; 305(3):1024-36. PubMed ID: 12649296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination treatment of the partial D2 agonist terguride with the D1 agonist SKF 82958 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys.
    Akai T; Ozawa M; Yamaguchi M; Mizuta E; Kuno S
    J Pharmacol Exp Ther; 1995 Apr; 273(1):309-14. PubMed ID: 7714782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.